drugset
drugset / Trial / NCT01442714

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

NCT01442714 ↗

Phase 2 Terminated 33 enrolled Stanford University Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.

Timeline

Start
2011-08
Primary completion
2014-03
Completion
2014-05

Outcome

Outcome not reported

Stopped: “Lack of efficacy - Inability to meet the primary response endpoint”

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Lenalidomide Other / unclassified 50 mg Oral

Indications

acute myeloid leukemia myelodysplastic syndrome